title: The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER).
abstract: BACKGROUND
  While guidelines for preventing chemotherapy-induced nausea and vomiting (CINV) are widely available, clinical uptake of guidelines remains low. Our objective was to evaluate the effect of guideline-consistent CINV prophylaxis (GCCP) on patient outcomes.
  
  
  METHODS
  This prospective, observational multicenter study enrolled chemotherapy-naive adults initiating single-day highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer. Patients completed 6-day daily diaries beginning with cycle 1 for up to three chemotherapy cycles. The primary study end point, complete response (no emesis and no use of rescue therapy) during 120 h after cycle 1 chemotherapy, was compared between GCCP and guideline-inconsistent CINV prophylaxis (GICP) cohorts using multivariate logistic regression, adjusting for potential confounding factors.
  
  
  RESULTS
  In cycle 1 (N=991), use of GCCP was 55% and 46% during acute and delayed phases, respectively, and 29 % for the overall study period (acute plus delayed phases). Complete response was recorded by 172/287 (59.9%) and 357/704 (50.7%) patients in GCCP and GICP cohorts, respectively (P=0.008). The adjusted odds ratio for complete response was 1.43 (95% confidence interval 1.04-1.97; P=0.027) for patients receiving GCCP versus GICP.
  
  
  CONCLUSIONS
  GCCP reduces the incidence of CINV after single-day HEC and MEC.
authors.affiliation: Medical Oncology and Radiation, IMO Clinique de Genolier, Genolier, Switzerland. Electronic address: maapro@genolier.net.
authors.forename: M
authors.initials: M
authors.lastname: Aapro
authors.affiliation: School of Nursing Midwifery and Social Work, University of Manchester, Manchester, UK.
authors.forename: A
authors.initials: A
authors.lastname: Molassiotis
authors.affiliation: Hematology-Oncology, Luxembourg Medical Center, Luxembourg, Luxembourg.
authors.forename: M
authors.initials: M
authors.lastname: Dicato
authors.affiliation: Hospital de Cabuenes, Gijón, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Peláez
authors.affiliation: Medical Oncology, Hospital General Universitario de Elche, Elche, Spain.
authors.forename: Á
authors.initials: Á
authors.lastname: Rodríguez-Lescure
authors.affiliation: Oncologic Institute of the Veneto, Padova, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Pastorelli
authors.affiliation: Global Health Outcomes, Merck Sharp & Dohme Corp., Whitehouse Station, USA.
authors.forename: L
authors.initials: L
authors.lastname: Ma
authors.affiliation: Global Health Outcomes, Merck Sharp & Dohme Corp., Whitehouse Station, USA.
authors.forename: T
authors.initials: T
authors.lastname: Burke
authors.affiliation: Global Health Outcomes, Merck Sharp & Dohme Corp., Whitehouse Station, USA.
authors.forename: A
authors.initials: A
authors.lastname: Gu
authors.affiliation: Institute of Hematology and Medical Oncology, IDIBAPS, University of Barcelona, Barcelona, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Gascon
authors.affiliation: Medical Oncology, Santa Maria Hospital, Terni, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Roila
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D019983:Guideline Adherence; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D014839:Vomiting / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents